WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='3.238.180.174'

Recent Press Releases – Shroom Investor 🍄

LATEST PRESS RELEASES

1 views9 min read

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin
- Rapid, robust, and clinically significant reduction of depression symptoms observed after a single dose of CYB003, with a clear incremental benefit of a second dose -- Primary efficacy endpoint achieved with an impressive mean -14 point difference in Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline betwe... Read More...
247 views4 min read

Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing

Optimi Health
VANCOUVER, British Columbia, Nov. 28, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, streng... Read More...
12 views4 min read

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Silo Pharma
MedSpray’s patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer’s disease, and anorexia ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company ... Read More...
Calendar29 views2 min read

Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023

Cybin
- Company to share topline Phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive disorder -TORONTO, November 16, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to... Read More...
M & A25 views8 min read

Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp

Psyence Group
TORONTO, Nov. 15, 2023 -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration stat... Read More...
265 views4 min read

US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives

BetterLife Pharma
VANCOUVER, British Columbia, Nov. 15, 2023 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that its patent application for BETR-001 and LSD d... Read More...
26359 views7 min read

Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders

Cybin
TORONTO, November 14, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce that it has closed its previous... Read More...
37 views4 min read

Red Light Holland Re-Engages Former Health Minister, the Honourable, Tony P. Clement, as Senior Advisor to Advisory Board

Red Light Holland
Toronto, Ontario--(Newsfile Corp. - November 14, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreati... Read More...
M & A35 views8 min read

Red Light Holland Psilocybin Microdosing Capsules Aimed to Be Distributed in Emerging Markets Pass Four Month Stability Testing by C-CREST Laboratories in Montreal, Canada

Red Light Holland
Red Light Holland's natural psilocybin microdosing capsules developed from psilocybin truffles grown in the Company's farm in The Netherlands, have received the results of four months stability tests for the capsules, confirming stability of psilocybin.Confirmation of stability of psilocybin, at four months, follows the previously announc... Read More...
34 views8 min read

Cybin Announces up to US$64 Million Offering of Units

Cybin
TORONTO, November 10, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce a firm commitment underwritten ... Read More...
37 views2 min read

Optimi Health Resolves Dispute

Optimi Health
VANCOUVER, British Columbia, Nov. 10, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi") is pleased to announce the successful resolution of a dispute that arose in connection with a termination notice related to a supply agreement ("the Supply Agreement") signed with a private entity on May 4, 2023. Optimi is pl... Read More...
16 views2 min read

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Silo Pharma
ENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traum... Read More...
35 views7 min read

Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test

Revive Therapeutics
Potential world-first patented biomarker for long COVID Evaluating diagnostic companion with Bucillamine for long COVID TORONTO, Nov. 06, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medi... Read More...
26 views8 min read

Red Light Holland Engages Dr. Taras Nahirny, as Medical Advisor, to Help with Distribution of Company’s Homogenized Psilocybin Microdosing Capsules and Help Advocate for Easier, but Regulated Access in Canada

Red Light Holland
Toronto, Ontario--(Newsfile Corp. - November 2, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilo... Read More...
13 views3 min read

Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing

Optimi Health
Optimi Health Corp.VANCOUVER, British Columbia, Nov. 02, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is plea... Read More...
18 views12 min read

Breakthrough Results: Cybin’s CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose

Cybin
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) -- For reference, pooled data from 232... Read More...
26 views8 min read

Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline

Cybin
- Company to host conference call to discuss positive Phase 2 CYB003 interim results today, November 1, 2023 at 11:00 a.m. ET -- Complete Phase 2 topline data for CYB003 in MDD expected in Q4 2023 -TORONTO, November 01, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharma... Read More...
27 views16 min read

Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) -- For reference, pooled data from 232... Read More...
534 views8 min read

Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements

Mydecine Innovations Group
VANCOUVER, British Columbia, Oct. 31, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is... Read More...
574 views6 min read

Psyence Production Expands Capability

Psyence Group
TORONTO, Oct. 30, 2023 -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), is pleased to provide the following update on Psyence Production. Psyence Production is a division of Psyence that oversees its psilocybin ... Read More...
CalendarFinancials40 views3 min read

COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023

COMPASS Pathways plc
COMPASS PathwaysLONDON, Oct. 24, 2023 -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2023, and provide an update on recent business developments on November 2... Read More...
M & A36 views12 min read

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

Cybin
This news release constitutes a "designated news release" for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023.- Combined portfolios create the industry’s largest, most advanced, well-protected deuterated DMT program -- Combination creates the largest ... Read More...
13 views0 min read

Mydecine Innovations Group gearing up for human trials after completing Aquis listing

Mydecine Innovations Group
London, UK --News Direct-- Mydecine Innovations Group Inc Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company's ambitious goals in the psychedelic medicine sector.Bartch explains that Mydecine focuses on developing "second generation" drugs de... Read More...
17 views4 min read

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

Revive Therapeutics
Revive Therapeutics Ltd.TORONTO, Oct. 11, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophil... Read More...
602 views7 min read

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings

Mydecine Innovations Group
VANCOUVER, British Columbia, Oct. 10, 2023 -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD... Read More...
501 views4 min read

Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO

Mydecine Innovations Group
VANCOUVER, British Columbia, Oct. 05, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to ... Read More...
Calendar194 views4 min read

Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date

Mydecine Innovations Group
VANCOUVER, British Columbia, Sept. 27, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to... Read More...
263 views6 min read

Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial

Cybin
TORONTO, September 26, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced an agreement with Fluence, a leading continuing... Read More...
444 views4 min read

Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing

Mydecine Innovations Group
VANCOUVER, British Columbia, Sept. 20, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased t... Read More...
176 views3 min read

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Silo Pharma
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on posi... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!